These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 37270367)

  • 1. Vaccination, human mobility, and COVID-19 health outcomes: Empirical comparison before and during the outbreak of SARS-Cov-2 B.1.1.529 (Omicron) variant.
    Hu S; Xiong C; Zhao Y; Yuan X; Wang X
    Vaccine; 2023 Aug; 41(35):5097-5112. PubMed ID: 37270367
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vaccine effectiveness against SARS-CoV-2 infection or COVID-19 hospitalization with the Alpha, Delta, or Omicron SARS-CoV-2 variant: A nationwide Danish cohort study.
    Gram MA; Emborg HD; Schelde AB; Friis NU; Nielsen KF; Moustsen-Helms IR; Legarth R; Lam JUH; Chaine M; Malik AZ; Rasmussen M; Fonager J; Sieber RN; Stegger M; Ethelberg S; Valentiner-Branth P; Hansen CH
    PLoS Med; 2022 Sep; 19(9):e1003992. PubMed ID: 36048766
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness of BNT162b2 and CoronaVac COVID-19 vaccination against asymptomatic and symptomatic infection of SARS-CoV-2 omicron BA.2 in Hong Kong: a prospective cohort study.
    Tsang NNY; So HC; Cowling BJ; Leung GM; Ip DKM
    Lancet Infect Dis; 2023 Apr; 23(4):421-434. PubMed ID: 36521506
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Disease severity and efficacy of homologous vaccination among patients infected with SARS-CoV-2 Delta or Omicron VOCs, compared to unvaccinated using main biomarkers.
    Ali AM; Tofiq AM; Rostam HM; Ali KM; Tawfeeq HM
    J Med Virol; 2022 Dec; 94(12):5867-5876. PubMed ID: 36029103
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Vaccine Efficacy Against the SARS-CoV-2 Omicron: A Systemic Review and Meta-Analysis.
    Zou Y; Huang D; Jiang Q; Guo Y; Chen C
    Front Public Health; 2022; 10():940956. PubMed ID: 35910897
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness of COVID-19 vaccines against SARS-CoV-2 Omicron variants during two outbreaks from March to May 2022 in Quzhou, China.
    Yin Z; Fang Q; Wen T; Zheng C; Fu C; Wang S; Li J; Gong X
    Hum Vaccin Immunother; 2023 Dec; 19(1):2163813. PubMed ID: 36704960
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness of a booster dose of COVID-19 vaccines during an outbreak of SARS-CoV-2 Omicron BA.2.2 in China: A case-control study.
    Zhang X; Wang Y; Hu C; Xu P; Ma L; Liu L; Sun J; Liu Y; Yang H; Pan F; Hu J; Cao C; Cheng K; Gao D; Lyu Y; Qin W
    Hum Vaccin Immunother; 2023 Dec; 19(1):2194189. PubMed ID: 36998173
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Facing the Omicron variant-how well do vaccines protect against mild and severe COVID-19? Third interim analysis of a living systematic review.
    Külper-Schiek W; Piechotta V; Pilic A; Batke M; Dreveton LS; Geurts B; Koch J; Köppe S; Treskova M; Vygen-Bonnet S; Waize M; Wichmann O; Harder T
    Front Immunol; 2022; 13():940562. PubMed ID: 36091023
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness of mRNA-1273, BNT162b2, and BBIBP-CorV vaccines against infection and mortality in children in Argentina, during predominance of delta and omicron covid-19 variants: test negative, case-control study.
    Castelli JM; Rearte A; Olszevicki S; Voto C; Del Valle Juarez M; Pesce M; Iovane AN; Paz M; Chaparro ME; Buyayisqui MP; Markiewicz MB; Landoni M; Giovacchini CM; Vizzotti C
    BMJ; 2022 Nov; 379():e073070. PubMed ID: 36450402
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vaccine effectiveness against SARS-CoV-2 reinfection during periods of Alpha, Delta, or Omicron dominance: A Danish nationwide study.
    Nielsen KF; Moustsen-Helms IR; Schelde AB; Gram MA; Emborg HD; Nielsen J; Hansen CH; Andersen MA; Meaidi M; Wohlfahrt J; Valentiner-Branth P
    PLoS Med; 2022 Nov; 19(11):e1004037. PubMed ID: 36413551
    [TBL] [Abstract][Full Text] [Related]  

  • 11. COVID-19 Vaccine Effectiveness during a Prison Outbreak when Omicron was the Dominant Circulating Variant-Zambia, December 2021.
    Simwanza J; Hines JZ; Sinyange D; Sinyange N; Mulenga C; Hanyinza S; Sakubita P; Langa N; Nowa H; Gardner P; Saasa N; Chitempa G; Simpungwe J; Malambo W; Hamainza B; Chipimo PJ; Kapata N; Kapina M; Musonda K; Liwewe M; Mwale C; Fwoloshi S; Mulenga LB; Agolory S; Mukonka V; Chilengi R
    Am J Trop Med Hyg; 2022 Nov; 107(5):1055-1059. PubMed ID: 36096406
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association Between Vaccination Coverage Disparity and the Dynamics of the COVID-19 Delta and Omicron Waves in the US.
    Cuadros DF; Moreno CM; Musuka G; Miller FD; Coule P; MacKinnon NJ
    Front Med (Lausanne); 2022; 9():898101. PubMed ID: 35775002
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protection against symptomatic infection with delta (B.1.617.2) and omicron (B.1.1.529) BA.1 and BA.2 SARS-CoV-2 variants after previous infection and vaccination in adolescents in England, August, 2021-March, 2022: a national, observational, test-negative, case-control study.
    Powell AA; Kirsebom F; Stowe J; Ramsay ME; Lopez-Bernal J; Andrews N; Ladhani SN
    Lancet Infect Dis; 2023 Apr; 23(4):435-444. PubMed ID: 36436536
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness of ChAdOx1 nCoV-19 vaccine against SARS-CoV-2 infection during the delta (B.1.617.2) variant surge in India: a test-negative, case-control study and a mechanistic study of post-vaccination immune responses.
    Thiruvengadam R; Awasthi A; Medigeshi G; Bhattacharya S; Mani S; Sivasubbu S; Shrivastava T; Samal S; Rathna Murugesan D; Koundinya Desiraju B; Kshetrapal P; Pandey R; Scaria V; Kumar Malik P; Taneja J; Binayke A; Vohra T; Zaheer A; Rathore D; Ahmad Khan N; Shaman H; Ahmed S; Kumar R; Deshpande S; Subramani C; Wadhwa N; Gupta N; Pandey AK; Bhattacharya J; Agrawal A; Vrati S; Bhatnagar S; Garg PK;
    Lancet Infect Dis; 2022 Apr; 22(4):473-482. PubMed ID: 34838183
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness of primary series and booster vaccination against SARS-CoV-2 infection and hospitalisation among adolescents aged 12-17 years in Singapore: a national cohort study.
    Chiew CJ; Premikha M; Chong CY; Wei WE; Ong B; Lye DC; Heng D; Lee VJ; Tan KB
    Lancet Infect Dis; 2023 Feb; 23(2):177-182. PubMed ID: 36182678
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative complete scheme and booster effectiveness of COVID-19 vaccines in preventing SARS-CoV-2 infections with SARS-CoV-2 Omicron (BA.1) and Delta (B.1.617.2) variants: A case-case study based on electronic health records.
    Kislaya I; Peralta-Santos A; Borges V; Vieira L; Sousa C; Ferreira B; Pelerito A; Gomes JP; Leite PP; Nunes B; ; Machado A; Rodrigues AP; Peixoto VR; Casaca P; Fernandes E; Rodrigues E; Ferreira R; Isidro J; Pinto M; Duarte S; Santos D; Meneses L; Almeida JP; Matias A; Freire S; Grilo T
    Influenza Other Respir Viruses; 2023 Mar; 17(3):e13121. PubMed ID: 36935845
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness of Booster Vaccinations on the Control of COVID-19 during the Spread of Omicron Variant in Malaysia.
    Wong MTJ; Dhaliwal SS; Balakrishnan V; Nordin F; Norazmi MN; Tye GJ
    Int J Environ Res Public Health; 2023 Jan; 20(2):. PubMed ID: 36674401
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vaccine effectiveness of BNT162b2 and CoronaVac against SARS-CoV-2 omicron infection and related hospital admission among people with substance use disorder in Hong Kong: a matched case-control study.
    Huang C; Wei Y; Yan VKC; Ye X; Kang W; Yiu HHE; Shami JJP; Cowling BJ; Tse ML; Castle DJ; Chui CSL; Lai FTT; Li X; Wan EYF; Wong CKH; Hayes JF; Chang WC; Chung AKK; Lau CS; Wong ICK; Chan EW
    Lancet Psychiatry; 2023 Jun; 10(6):403-413. PubMed ID: 37141907
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Durability of BNT162b2 vaccine against hospital and emergency department admissions due to the omicron and delta variants in a large health system in the USA: a test-negative case-control study.
    Tartof SY; Slezak JM; Puzniak L; Hong V; Xie F; Ackerson BK; Valluri SR; Jodar L; McLaughlin JM
    Lancet Respir Med; 2022 Jul; 10(7):689-699. PubMed ID: 35468336
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relative vaccine effectiveness against Delta and Omicron COVID-19 after homologous inactivated vaccine boosting: a retrospective cohort study.
    Tang L; Zhang Y; Wang F; Wu D; Qian ZH; Zhang R; Wang AB; Huang C; Wang H; Ye Y; Lu M; Wang C; Ma YT; Pan J; Li YF; Lv XY; An Z; Rodewald L; Wang XY; Shao YM; Wu ZY; Yin Z
    BMJ Open; 2022 Nov; 12(11):e063919. PubMed ID: 36368753
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.